NCT05735184 2026-03-13
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
Phase 1 Recruiting
Clinical Trials
10 trialsNCT06769490 2026-02-11
Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT02834390 2025-03-05
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Completed
NCT03723681 2022-07-29
Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Completed
NCT03552029 2022-05-20
Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Terminated
NCT01411267 2022-04-04
AC220 for Children With Relapsed/Refractory ALL or AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT00462761 2020-05-11
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Daiichi Sankyo
Phase 1 Completed
NCT01049893 2019-02-12
Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Completed
NCT01390337 2019-02-12
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Completed
NCT01468467 2019-02-12
A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Completed